- Trials with a EudraCT protocol (41)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
41 result(s) found for: ischemic stroke.
Displaying page 1 of 3.
EudraCT Number: 2014-003123-22 | Sponsor Protocol Number: JCS-CBG-2014-01 | Start Date*: 2015-01-02 |
Sponsor Name:José Castillo Sanchez | ||
Full Title: "Randomized clinical trial with two parallel groups, double-blind, placebo-controlled trial to investigate whether administration of CBG000592 (riboflavin/vitamin B2) in patients with acute ischemi... | ||
Medical condition: Acute ischemic stroke | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005906-32 | Sponsor Protocol Number: WAKE-UP | Start Date*: 2012-09-24 | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial | |||||||||||||
Medical condition: Patients with acute ischemic stroke proven by MRI and unknown time from symptom onset which otherwise fulfil the approval criteria for intravenous thrombolysis in acute stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Completed) GB (Completed) DK (Completed) ES (Completed) NL (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001185-41 | Sponsor Protocol Number: POINT | Start Date*: 2013-11-26 | ||||||||||||||||
Sponsor Name:University of California San Francisco Stroke Sciences Group | ||||||||||||||||||
Full Title: Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, a randomized, double blind, multicentre clinical trial | ||||||||||||||||||
Medical condition: Transient Ischemic Attack and Minor Stroke | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Completed) DE (Prematurely Ended) FI (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-002864-33 | Sponsor Protocol Number: NTA0903 | Start Date*: 2014-12-16 | ||||||||||||||||
Sponsor Name:The Florey Institute of Neuroscience and Mental Health | ||||||||||||||||||
Full Title: EXTEND (International): Extending the time for Thrombolysis in Emergency Neurological Deficits (International) | ||||||||||||||||||
Medical condition: Ischaemic stroke | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003895-38 | Sponsor Protocol Number: D5134C00001 | Start Date*: 2014-02-11 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A randomised, double-blind, multinational study to prevent major vascular events with Ticagrelor compared to Aspirin(ASA) in patients with acute ischaemic stroke or Transient Ischemic Attack (TIA).... | |||||||||||||
Medical condition: ischaemic stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) SK (Completed) BE (Completed) SE (Completed) DE (Completed) IT (Completed) ES (Completed) BG (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000768-27 | Sponsor Protocol Number: BAY59-7939/16573 | Start Date*: 2015-01-29 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Multicenter, randomized, double-blind, double-dummy, active-comparator, event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients w... | |||||||||||||
Medical condition: Embolic stroke of undetermined source (ESUS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) IE (Prematurely Ended) PT (Prematurely Ended) CZ (Completed) BE (Completed) ES (Completed) IT (Prematurely Ended) HU (Completed) FI (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003444-24 | Sponsor Protocol Number: 1160.189 | Start Date*: 2014-11-21 | ||||||||||||||||||||||||||
Sponsor Name:Unilfarma - União Internacional de Lab. Farmacêuticos, Lda. | ||||||||||||||||||||||||||||
Full Title: Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acet... | ||||||||||||||||||||||||||||
Medical condition: A study to compare dabigatran etexilate to acetylsalicylic acid in preventing recurrent stroke for patients that already had a stroke caused by an embolus (clot). Despite testing, it is unknown wh... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: PT (Completed) DE (Completed) BE (Completed) AT (Completed) HU (Completed) IT (Completed) SE (Completed) SI (Completed) ES (Completed) CZ (Completed) SK (Completed) PL (Completed) HR (Completed) GR (Completed) EE (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001824-43 | Sponsor Protocol Number: DS1040-A-U103 | Start Date*: 2016-02-04 |
Sponsor Name:Daiichi Sankyo, Inc. | ||
Full Title: A Phase 1b/2, multi-center, double-blind (principal investigators and study subjects blinded, sponsor unblinded), placebo-controlled, randomized, single-ascending dose study to assess the safety, p... | ||
Medical condition: DS-1040b is an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) intended to be used for the treatment of thrombotic diseases including acute ischemic stroke (A... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) FR (Completed) GB (Completed) CZ (Completed) ES (Completed) SK (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-005109-19 | Sponsor Protocol Number: ATTICUS | Start Date*: 2015-11-10 |
Sponsor Name:University Hospital Tuebingen | ||
Full Title: Apixaban for treatment of embolic stroke of undetermined source | ||
Medical condition: Patients with embolic stroke of undetermined source and at least on risk factor for cardiac embolism | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-001675-32 | Sponsor Protocol Number: ARTE | Start Date*: 2014-10-20 | |||||||||||
Sponsor Name:IUCPQ | |||||||||||||
Full Title: Aspirin versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation with the Edwards Valve. A Randomized Study (the ARTE trial). | |||||||||||||
Medical condition: Incidence of death, MI, ischemic stroke/Transient ischemic attack (TIA) or life threatening/major bleeding at 3-month follow-up. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002944-25 | Sponsor Protocol Number: EuroHyp-1 | Start Date*: 2014-08-20 | |||||||||||
Sponsor Name:Universitätsklinikum Erlangen | |||||||||||||
Full Title: EuroHYP-1: European multicentre, randomised, phase III clinical trial of therapeutic hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke | |||||||||||||
Medical condition: Acute ischaemic stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) FI (Completed) IT (Completed) IE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005569-58 | Sponsor Protocol Number: BAY59-7939/17454 | Start Date*: 2015-09-23 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of Rivaroxaban to reduce the risk of major thrombotic vascular event... | |||||||||||||
Medical condition: Peripheral artery disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) AT (Completed) ES (Completed) HU (Completed) GB (Completed) FR (Completed) PT (Completed) SE (Completed) BE (Completed) BG (Completed) DK (Completed) DE (Completed) NL (Completed) PL (Completed) SK (Completed) LT (Completed) LV (Completed) RO (Completed) EE (Completed) FI (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005698-21 | Sponsor Protocol Number: EFC11570 | Start Date*: 2013-03-05 | |||||||||||
Sponsor Name:sanofi-aventis Recherche & Développement | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recentl... | |||||||||||||
Medical condition: Acute coronary syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) BE (Completed) NO (Completed) EE (Completed) LT (Completed) HU (Completed) ES (Completed) CZ (Completed) LV (Completed) DE (Completed) IT (Completed) BG (Completed) FI (Completed) AT (Completed) PT (Completed) DK (Completed) NL (Completed) PL (Completed) SK (Completed) SI (Completed) HR (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000620-28 | Sponsor Protocol Number: LPS14245 | Start Date*: 2015-07-06 | |||||||||||
Sponsor Name:sanofi-aventis groupe | |||||||||||||
Full Title: A Multi-Country, Multicenter, Single-Arm, Open-Label Study to Document the Safety, Tolerability and Effect of Alirocumab on atherogenic lipoproteins in High Cardio-Vascular Risk Patients With Sever... | |||||||||||||
Medical condition: Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) CZ (Completed) SK (Completed) BE (Completed) IT (Completed) HU (Completed) AT (Completed) DE (Completed) FR (Completed) SE (Completed) ES (Completed) FI (Completed) PL (Completed) GR (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001384-23 | Sponsor Protocol Number: REG1-CLIN310 | Start Date*: 2013-10-30 | |||||||||||
Sponsor Name:Regado Biosciences, Inc. | |||||||||||||
Full Title: A RANDOMIZED, OPEN-LABEL, MULTI-CENTER, ACTIVE-CONTROLLED, PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF THE REG1 ANTICOAGULATION SYSTEM COMPARED TO BIVALIRUDIN IN PATIENTS UNDERGOIN... | |||||||||||||
Medical condition: Coronary Artery Disease (CAD) in patients undergoing Percutaneous Coronary Intervention (PCI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) EE (Prematurely Ended) DE (Prematurely Ended) NL (Completed) PT (Prematurely Ended) AT (Completed) GB (Completed) IT (Prematurely Ended) BE (Completed) SK (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004180-43 | Sponsor Protocol Number: BAY59-7939/15786 | Start Date*: 2013-03-13 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People u... | |||||||||||||
Medical condition: Prevention of major cardiovascular events in patients with coronary or peripheral artery disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) SE (Completed) CZ (Completed) FI (Completed) IT (Completed) HU (Completed) NL (Completed) GB (Completed) SK (Completed) DK (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000657-50 | Sponsor Protocol Number: PM1116197 | Start Date*: 2014-05-27 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||||||||||||||||||||||||||||
Full Title: A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo (PM1116197)... | ||||||||||||||||||||||||||||
Medical condition: | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: SE (Completed) NL (Prematurely Ended) IT (Completed) DE (Completed) BE (Completed) SK (Completed) DK (Completed) ES (Completed) NO (Completed) GB (Completed) CZ (Completed) HU (Completed) EE (Completed) GR (Prematurely Ended) PL (Completed) BG (Completed) RO (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-002518-11 | Sponsor Protocol Number: 8835-004 | Start Date*: 2014-01-16 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES ME... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) NL (Completed) GB (Completed) IT (Completed) ES (Completed) BG (Completed) PL (Completed) GR (Completed) HR (Completed) SK (Completed) LT (Completed) LV (Completed) CZ (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001397-33 | Sponsor Protocol Number: ARTESIA | Start Date*: 2015-09-15 | |||||||||||
Sponsor Name:Hamilton Health Sciences through the Population Health Research Institute | |||||||||||||
Full Title: APIXABAN FOR THE REDUCTION OF THROMBO-EMBOLISM IN PATIENTS WITH DEVICE-DETECTED SUB-CLINICAL ATRIAL FIBRILLATION | |||||||||||||
Medical condition: Device-detected sub-clinical atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) NL (Ongoing) GB (GB - no longer in EU/EEA) BE (Completed) DE (Ongoing) SE (Completed) ES (Ongoing) DK (Completed) HU (Completed) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002414-39 | Sponsor Protocol Number: MK-3102-018 | Start Date*: 2013-01-04 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) NL (Prematurely Ended) DE (Completed) NO (Completed) SE (Prematurely Ended) AT (Prematurely Ended) CZ (Completed) ES (Prematurely Ended) FI (Completed) DK (Prematurely Ended) IT (Completed) BE (Completed) SK (Prematurely Ended) LT (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended) HR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
